Skip to main
TRDA

Entrada Therapeutics (TRDA) Stock Forecast & Price Target

Entrada Therapeutics (TRDA) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Entrada Therapeutics is poised for success in the biopharmaceutical market with its innovative Endosomal Escape Vehicle (EEV)-therapeutics, which have the potential to unlock previously inaccessible intracellular targets and treat a variety of diseases. The company's partnership with Vertex Pharmaceuticals to develop a treatment for myotonic dystrophy type 1 (DM1) is a strong indicator of the potential success of the platform. With ongoing trials progressing well and a potential for accelerated approval in the US, this stock is a strong buy with a price target of $20.

Bears say

Entrada Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Endosomal Escape Vehicle (EEV)-therapeutics. Although the company has partnered with Vertex Pharmaceuticals for a clinical-stage program for myotonic dystrophy type 1, the efficacy data for their oligonucleotide programs is concerning as it shows a lower splicing index reduction compared to competitors. Additionally, their financials show high capital expenditures with little revenue, making their future prospects uncertain.

Entrada Therapeutics (TRDA) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Entrada Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Entrada Therapeutics (TRDA) Forecast

Analysts have given Entrada Therapeutics (TRDA) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Entrada Therapeutics (TRDA) has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Entrada Therapeutics (TRDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.